<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Allergy</journal-id><journal-title-group><journal-title>Clinical and Translational Allergy</journal-title></journal-title-group><issn pub-type="epub">2045-7022</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3723478</article-id><article-id pub-id-type="publisher-id">2045-7022-3-S3-P124</article-id><article-id pub-id-type="doi">10.1186/2045-7022-3-S3-P124</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Is molecular allergology cost-effective and cost saving in children with suspected peanut allergy compared to double blind placebo controlled food challenge (DBPCFC), open oral food challenge and skin prick test in Sweden?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Glaumann</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Hermansson</surname><given-names>L-L</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Mascialino</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hubben</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Borres</surname><given-names>MP</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Nilsson</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Clinical Science and Education, S&#x000f6;dersjukhuset, Karolinska Institutet, Stockholm, Sweden</aff><aff id="I2"><label>2</label>Thermo Fisher Scientific, Uppsala, Sweden</aff><aff id="I3"><label>3</label>BaseCase Software, Berlin, Germany</aff><aff id="I4"><label>4</label>Department of Paediatrics, Sahlgrenska Academy of Gothenburg University, Gothenburg, Sweden</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2013</year></pub-date><volume>3</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Food Allergy and Anaphylaxis Meeting (FAAM 2013): Abstracts</named-content><named-content content-type="supplement-editor">Karin Hoffmann-Sommergruber, Antonella Muraro, Berber Vlieg-Boerstra, Carsten Bindslev-Jensen, Anthony Dubois, Phillippe Eigenmann, Susanne Halken, Giovanni Pajno, Lars K Poulsen, Graham Roberts, Ronald van Ree, Valerie Verhasselt and Thomas Werfel</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the EAACI.</named-content></supplement><fpage>P124</fpage><lpage>P124</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Glaumann et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Glaumann et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ctajournal.com/content/3/S3/P124"/><conference><conf-date>7-9 February 2013</conf-date><conf-name>Food Allergy and Anaphylaxis Meeting (FAAM 2013)</conf-name><conf-loc>Nice, France</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Peanuts are one of the most common foods causing allergic reactions in children. IgE-ab sensitization to peanut has been reported in 7&#x02013;11% of children in Western countries and the prevalence of peanut allergy (PA) in children varies between 0.75% and 3%. Given the PA impact on quality-of-life (QoL), accurate diagnosis is crucial because many sensitized individuals are actually tolerant to peanut. Peanut sensitization established by IgE antibodies (IgE-ab) in blood or skin prick test (SPT) often needs to be confirmed by the &#x0201c;gold standard&#x0201d; Double-blind placebo-controlled food challenge (DBPCFC), a risky and expensive procedure. In clinical practice an open oral food challenge (OC) is performed instead of a DBPCFC. PA can be effectively diagnosed using molecular allergology (MA), identifying subjects at risk for PA reactions (IgE-ab to Ara h 1-2-3). No cost-effectiveness (CE) analyses are available on MA for allergy.</p></sec><sec sec-type="methods"><title>Methods</title><p>Three 5-year Markov models simulate the flow of 200 children PA suspected presenting to the general practitioner. The models compare different diagnostic approaches (DBPCFC, OC, SPT and MA), computing the cost-per-QALY (Quality Adjusted Life Year) gained based on data from the literature. Calculations were performed for Sweden and BaseCase&#x000ae; was used to present results. Care giver indirect costs are included in a sensitivity analysis.</p></sec><sec sec-type="results"><title>Results</title><p>In Sweden, cost-per-QALY is 3.66 for SPT, 3.22 for DBPCFC, 2.23 for OC and 4.34 for MA. The cost for different diagnostic approaches is:</p><p>- SPT: 44851 SEK</p><p>- DBPCFC: 24278 SEK</p><p>- OC: 33031SEK</p><p>- MA: 11267 SEK</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In Sweden, MA increases QoL, and it is associated with reduced costs per patient with respect to the other strategies. The hypothesized usage of MA could be a valid alternative and a useful diagnostic tool replacing the &#x0201c;gold standard&#x0201d; DBPCFC in selected cases, DBPCFC still being useful in subjects with conflicting immunological/clinical results.</p></sec><sec><title>Disclosure of interest</title><p>S Glaumann: None declared, L-L Hermansson: Employee of Thermo Fisher Scientific, B Mascialino: Employee of Thermo Fisher Scientific, G Hubben: Employee of BaseCase Software, M Borres: Employee of Thermo Fisher Scientific, C Nilsson: None declared.</p></sec></body></article>